Drug Discovery Platforms Market By Solution (Software, Services); By Function (Sequencing and Target Data Analysis, Docking, Molecular Modeling, Library & Database Preparation, Others); By End User (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Others); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Drug Discovery Platforms Market size was valued at USD 132.45 million in 2018 to USD 240.70 million in 2024 and is anticipated to reach USD 607.68 million by 2032, at a CAGR of 11.44% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Drug Discovery Platforms Market Size 2024
USD 240.70 Million
Drug Discovery Platforms Market, CAGR
11.44%
Drug Discovery Platforms Market Size 2032
USD 607.68 Million
The Drug Discovery Platforms Market is shaped by prominent players including Schrödinger, Certara, PerkinElmer (Revvity), Merative, Charles River Laboratories, Evotec SE, Chemaxon, OpenEye (Cadence Molecular Sciences), and Genedata. These companies maintain strong market positions through advanced software solutions, AI-driven analytics, and strategic collaborations with pharmaceutical and biotechnology firms. Competition focuses on enhancing molecular modeling, sequencing, and database management capabilities to accelerate drug development. Regionally, North America leads the market with a 38% share in 2024, supported by significant R&D investments, advanced healthcare infrastructure, and early adoption of digital discovery technologies.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
The Drug Discovery Platforms Market grew from USD 132.45 million in 2018 to USD 240.70 million in 2024 and is projected to reach USD 607.68 million by 2032.
Software led with 62% share in 2024, driven by AI-enabled tools and predictive analytics, while services held 38% share, boosted by rising outsourcing and integration support.
Sequencing and Target Data Analysis dominated with 35% share in 2024, followed by docking at 25% and molecular modeling at 20%, supporting advanced screening and structural biology.
Pharmaceutical companies held 48% share in 2024, followed by biotechnology firms at 28% and CROs at 18%, reflecting heavy investment in digital pipelines and outsourcing.
North America led with 38% share in 2024, followed by Asia Pacific at 27% and Europe at 15%, supported by R&D spending, biotech growth, and regulatory initiatives.
Market Segment Insights
By Solution
Software accounts for the dominant share of the Drug Discovery Platforms Market, holding 62% in 2024. Its leadership is driven by the growing adoption of AI-enabled platforms, machine learning algorithms, and cloud-based computational tools that streamline drug development. Software platforms improve predictive accuracy in target identification and reduce development costs, making them preferred by pharmaceutical and biotechnology firms. Services, with the remaining 38% share, are gaining traction due to increasing demand for outsourced expertise, customization, and integration support.
For instance, Exscientia reported that its AI-driven drug discovery platform had identified a novel molecule that advanced into Phase 1 clinical trials, reducing timeline and cost compared to conventional methods.
By Function
Sequencing and Target Data Analysis leads the function segment with 35% share in 2024, supported by rapid advancements in next-generation sequencing and data analytics for personalized medicine. Docking and molecular modeling follow with 25% and 20% shares respectively, as they play critical roles in virtual screening and structural biology. Library & database preparation holds around 12%, driven by the need for high-quality compound databases, while others collectively contribute 8%, including niche tools for specialized research areas.
For instance, Illumina launched the NovaSeq X Plus sequencer, capable of generating over 20,000 whole genomes annually, significantly boosting large-scale sequencing capacity.
By End User
Pharmaceutical companies dominate the end-user segment, holding 48% share in 2024, as they invest heavily in digital platforms to accelerate drug pipelines and reduce attrition rates. Biotechnology companies follow with 28% share, leveraging platforms for niche therapies and precision medicine. Contract Research Organizations (CROs) account for 18%, driven by increasing outsourcing of discovery processes. Others, including academic and research institutes, hold 6%, supporting early-stage innovation and collaborative projects.
Key Growth Drivers
Rising Demand for AI and Machine Learning Integration
The integration of AI and machine learning is a major driver in the Drug Discovery Platforms Market. These technologies enable faster target identification, predictive modeling, and optimization of clinical outcomes, reducing both time and cost of development. Companies are increasingly deploying AI-enabled software to analyze large biomedical datasets, improving accuracy in drug design. This shift enhances efficiency and supports the growing pipeline of precision medicine, positioning AI-driven solutions as a cornerstone of modern discovery processes.
For instance, Atomwise’s AI platform AtomNet uses deep convolutional neural networks to predict small molecule-protein binding in days, bypassing lengthy traditional screening methods and tackling 600+ unique disease targets.
Growing Investments in Precision Medicine
Expanding focus on precision medicine continues to accelerate platform adoption. Pharmaceutical and biotechnology companies rely on advanced discovery platforms to design therapies tailored to genetic, molecular, and patient-specific profiles. Rising prevalence of chronic and genetic disorders has fueled funding in targeted drug development, driving demand for sequencing and molecular modeling functions. Government and private sector investments in genomics, coupled with broader adoption of personalized therapies, are strengthening the market’s growth trajectory and reshaping traditional R&D models.
For instance, in February 2025, the Government of Canada launched the Canadian Genomics Strategy with an investment of $175.1 million over seven years to accelerate commercialization and adoption of genomics in personalized medicine, advanced diagnostics, and novel therapeutics for conditions such as rare diseases and cancer.
Increasing Outsourcing to CROs
Pharmaceutical and biotech companies are outsourcing more discovery functions to Contract Research Organizations (CROs) to lower operational costs and improve efficiency. CROs provide specialized expertise, advanced tools, and access to global research networks, allowing companies to streamline drug pipelines. This outsourcing trend also reduces the burden of maintaining in-house infrastructure, particularly for small and mid-sized enterprises. Growing reliance on CROs for sequencing, molecular modeling, and database preparation is a significant factor propelling the expansion of services in the market.
Key Trends & Opportunities
Adoption of Cloud-Based Platforms
Cloud deployment is emerging as a transformative trend in the Drug Discovery Platforms Market. Cloud-enabled solutions allow seamless access to data, scalability of operations, and improved collaboration across global research teams. The shift to cloud reduces upfront infrastructure costs, promotes faster data processing, and enables real-time analytics, which is vital in accelerating discovery cycles. This trend creates opportunities for platform providers to offer secure, integrated, and subscription-based models tailored to diverse research needs.
For instance, BenevolentAI announced a strategic overhaul focusing on AI-driven drug discovery powered by cloud platforms, enabling scalable and faster analysis of complex datasets to accelerate research pipelines.
Expansion in Emerging Markets
Emerging markets such as Asia-Pacific and Latin America are creating new opportunities for drug discovery platforms. Growing healthcare investments, rising patient pools, and increasing government support for life sciences research drive demand in these regions. Countries like China and India are witnessing rapid adoption of sequencing and AI-based platforms, supported by biotech startups and academic partnerships. This expansion provides significant opportunities for global players to establish strategic collaborations, offer cost-effective solutions, and strengthen regional market presence.
For instance, WuXi AppTec announced the launch of a new drug discovery facility in Changzhou, China, equipped with AI-powered screening technologies to serve both domestic and international biopharma clients.
Key Challenges
High Implementation Costs
Despite technological progress, high upfront costs for deploying advanced discovery platforms remain a critical barrier. Smaller biotech firms and academic institutions often face funding constraints, limiting adoption of comprehensive software and services. Expenses related to AI integration, cloud infrastructure, and data security further raise financial hurdles. These costs challenge widespread market penetration, especially in resource-limited regions, slowing growth despite rising demand for precision-driven drug development.
Data Privacy and Security Concerns
Data integrity and security present major challenges for market players. Drug discovery relies on sensitive patient data, proprietary compound libraries, and genomic databases that are vulnerable to breaches and misuse. Compliance with stringent regulations such as GDPR and HIPAA further complicates data management. Ensuring secure handling of research data while maintaining global collaboration creates operational hurdles for platform providers, raising concerns among pharmaceutical and biotechnology stakeholders.
Regulatory Complexity in Drug Approval
The complex regulatory environment governing drug discovery slows market expansion. While platforms accelerate early-stage research, they must align with evolving global standards for safety, efficacy, and ethical compliance. Lengthy approval processes and variations across regions create inefficiencies, discouraging rapid adoption. Companies face delays in translating discoveries into clinical success, reducing the overall impact of digital platforms. This challenge underscores the need for harmonized regulations and supportive frameworks to streamline innovation pathways.
Regional Analysis
North America
North America dominates the Drug Discovery Platforms Market with a 38% share in 2024, generating USD 105.11 billion, up from USD 58.44 billion in 2018. It is projected to reach USD 266.10 billion by 2032, advancing at a CAGR of 11.5%. The region’s leadership is driven by high pharmaceutical R&D spending, rapid adoption of AI-enabled platforms, and a strong clinical trial ecosystem. The U.S. leads, supported by advanced infrastructure, robust government and private investments, while Canada and Mexico add momentum through rising CRO activities.
Europe
Europe holds a 15% share in 2024, with revenue of USD 41.64 billion, compared to USD 24.27 billion in 2018. The market is expected to grow to USD 95.41 billion by 2032, at a CAGR of 10.1%. Growth stems from strong regulatory backing for precision medicine, high demand for sequencing technologies, and strong collaborations between pharma firms and academic research institutions. Germany, France, and the UK dominate the regional landscape, supported by strong healthcare systems and investment in genomics innovation.
Asia Pacific
Asia Pacific accounts for a 27% share in 2024, valued at USD 74.25 billion, rising from USD 38.72 billion in 2018. It is projected to reach USD 204.25 billion by 2032, making it the fastest-growing region with a CAGR of 12.6%. China, Japan, and India drive demand through large patient pools, rapid healthcare digitization, and increased biotech investment. Regional governments’ support for AI-driven discovery and strong cost advantages in R&D outsourcing further position Asia Pacific as a key growth hub.
Latin America
Latin America represents a 4% share in 2024, with revenue of USD 10.48 billion, up from USD 5.84 billion in 2018. The market is expected to reach USD 23.20 billion by 2032, expanding at a CAGR of 9.6%. Brazil and Argentina are leading markets, supported by growing healthcare investment and modern drug discovery adoption. Rising outsourcing demand from pharmaceutical firms adds further growth, although infrastructure limitations and uneven funding remain barriers across the broader region.
Middle East
The Middle East accounts for a 2% share in 2024, valued at USD 5.47 billion, compared to USD 3.33 billion in 2018. The market is forecasted to reach USD 11.37 billion by 2032, advancing at a CAGR of 8.7%. Growth is fueled by healthcare modernization in GCC countries, digital transformation initiatives, and international collaborations. Israel strengthens the region’s profile with its innovation-driven biotech ecosystem, while demand for AI-powered discovery solutions gradually gains traction across emerging healthcare hubs.
Africa
Africa contributes a 1% share in 2024, generating USD 3.75 billion, rising from USD 1.85 billion in 2018. By 2032, the market is expected to reach USD 7.34 billion, at a CAGR of 7.9%. South Africa dominates with advanced infrastructure and expanding clinical research networks. Egypt and other nations are beginning to adopt digital drug discovery tools, though challenges such as limited funding and infrastructure gaps persist. Nevertheless, increasing partnerships, high disease burden, and government healthcare initiatives offer gradual growth opportunities.
Market Segmentations:
By Solution
Software
Services
By Function
Sequencing and Target Data Analysis
Docking
Molecular Modeling
Library & Database Preparation
Others
By End User
Pharmaceutical Companies
Biotechnology Companies
Contract Research Organizations (CROs)
Others
By Region
North America (U.S., Canada, Mexico)
Europe (UK, France, Germany, Italy, Spain, Russia, Rest of Europe)
Asia Pacific (China, Japan, South Korea, India, Australia, Southeast Asia, Rest of APAC)
Latin America (Brazil, Argentina, Rest of Latin America)
Middle East (GCC Countries, Israel, Turkey, Rest of Middle East)
Africa (South Africa, Egypt, Rest of Africa)
Competitive Landscape
The competitive landscape of the Drug Discovery Platforms Market is characterized by a mix of established pharmaceutical technology providers, specialized biotech firms, and Contract Research Organizations (CROs) competing to deliver advanced solutions. Leading companies such as Schrödinger, Certara, PerkinElmer (Revvity), Merative, and Charles River Laboratories hold significant market presence through comprehensive software portfolios, strong service networks, and global collaborations. Players like Evotec SE, Chemaxon, OpenEye (Cadence Molecular Sciences), and Genedata further strengthen competition with specialized offerings in molecular modeling, sequencing analytics, and database solutions. Strategic partnerships, mergers, and acquisitions are frequent as companies expand capabilities in AI, machine learning, and cloud-based platforms to gain a competitive edge. Firms increasingly focus on precision medicine, personalized therapies, and outsourcing services to align with evolving industry demand. Competition remains intense as emerging regional players in Asia-Pacific and Europe leverage cost advantages and niche expertise, creating a dynamic and innovation-driven market environment.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In September 2025, Eli Lilly launched TuneLab, an AI/ML platform that provides biotech firms access to discovery models trained on Lilly’s internal R&D data.
In January 2025, Valo Health and Novo Nordisk expanded their partnership to cover more drug programs for obesity, type 2 diabetes, and cardiovascular disease using Valo’s AI-driven discovery platform.
In July 2025, Elix and the Life Intelligence Consortium (LINC) announced the commercial launch of an AI-based drug discovery platform that uses advanced algorithms to accelerate drug development.
In July 2025, Eisai partnered with Elix, Inc. to use the Elix Discovery™ generative and predictive AI platform for small molecule discovery with advanced molecular design tools.
Report Coverage
The research report offers an in-depth analysis based on Solution, Function, End User and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
Adoption of AI and machine learning will enhance accuracy in drug discovery.
Cloud-based platforms will expand collaboration and data integration across global research teams.
Precision medicine will drive demand for sequencing and molecular modeling solutions.
Pharmaceutical companies will increase reliance on digital platforms to reduce R&D timelines.
Biotechnology startups will accelerate adoption of specialized discovery tools.
Outsourcing to CROs will grow as firms seek cost-effective research solutions.
Emerging markets will play a larger role in expanding platform adoption.
Strategic partnerships between tech firms and pharma companies will intensify.
Data security and compliance solutions will become integral to platform offerings.
Continuous innovation will shape competitive differentiation in advanced drug discovery platforms.
CHAPTER NO. 1: GENESIS OF THE MARKET
1.1 Market Prelude – Introduction & Scope
1.2 The Big Picture – Objectives & Vision
1.3 Strategic Edge – Unique Value Proposition
1.4 Stakeholder Compass – Key Beneficiaries CHAPTER NO. 2: EXECUTIVE LENS
2.1 Pulse of the Industry – Market Snapshot
2.2 Growth Arc – Revenue Projections (USD Million)
2.3. Premium Insights – Based on Primary Interviews CHAPTER NO. 3: DRUG DISCOVERY PLATFORMS MARKET FORCES & INDUSTRY PULSE
3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown
3.6 Price Trend Analysis
3.6.1 Regional Price Trend
3.6.2 Price Trend by Service CHAPTER NO. 4: KEY INVESTMENT EPICENTER
4.1 Regional Goldmines – High-Growth Geographies
4.2 Service Frontiers – Lucrative Service Categories
4.3 Application Sweet Spots – Emerging Demand Segments CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING
5.1 Momentum Metrics – Forecast & Growth Curves
5.2 Regional Revenue Footprint – Market Share Insights
5.3 Segmental Wealth Flow – Solution & End User Revenue CHAPTER NO. 6: TRADE & COMMERCE ANALYSIS
6.1. Import Analysis by Region
6.1.1. Global Drug Discovery Platforms Import Revenue By Region
6.2. Export Analysis by Region
6.2.1. Global Drug Discovery Platforms Export Revenue By Region CHAPTER NO. 7: COMPETITION ANALYSIS
7.1. Company Market Share Analysis
7.1.1. Global Drug Discovery Platforms: Company Market Share
7.2. Global Drug Discovery Platforms Company Revenue Market Share
7.3. Strategic Developments
7.3.1. Acquisitions & Mergers
7.3.2. New Service Launch
7.3.3. Regional Expansion
7.4. Competitive Dashboard
7.5. Company Assessment Metrics, 2024 CHAPTER NO. 8: DRUG DISCOVERY PLATFORMS MARKET – BY SOLUTION SEGMENT ANALYSIS
8.1. Drug Discovery Platforms Overview by Solution Segment
8.1.1. Drug Discovery Platforms Revenue Share By Solution
8.2. Software
8.3. Services CHAPTER NO. 9: DRUG DISCOVERY PLATFORMS MARKET – BY FUNCTION SEGMENT ANALYSIS
9.1. Drug Discovery Platforms Overview by Function Segment
9.1.1. Drug Discovery Platforms Revenue Share By Function
9.2. Sequencing and Target Data Analysis
9.3. Docking
9.4. Molecular Modeling
9.5. Library & Database Preparation
9.6. Others CHAPTER NO. 10: DRUG DISCOVERY PLATFORMS MARKET – BY END USER SEGMENT ANALYSIS
10.1. Drug Discovery Platforms Overview by End User Segment
10.1.1. Drug Discovery Platforms Revenue Share By End User
10.2. Pharmaceutical Companies
10.3. Biotechnology Companies
10.4. Contract Research Organizations (CROs)
10.5. Others CHAPTER NO. 11: DRUG DISCOVERY PLATFORMS MARKET – REGIONAL ANALYSIS
11.1. Drug Discovery Platforms Overview by Region Segment
11.1.1. Global Drug Discovery Platforms Revenue Share By Region
11.1.2. Region
11.1.3. Global Drug Discovery Platforms Revenue By Region
11.1.4. Solution
11.1.5. Global Drug Discovery Platforms Revenue By Solution
11.1.6. Function
11.1.7. Global Drug Discovery Platforms Revenue By Function
11.1.8. End User
11.1.9. Global Drug Discovery Platforms Revenue By End User CHAPTER NO. 12: NORTH AMERICA DRUG DISCOVERY PLATFORMS MARKET – COUNTRY ANALYSIS
12.1. North America Drug Discovery Platforms Overview by Country Segment
12.1.1. North America Drug Discovery Platforms Revenue Share By Region
12.2. North America
12.2.1. North America Drug Discovery Platforms Revenue By Country
12.2.2. Solution
12.2.3. North America Drug Discovery Platforms Revenue By Solution
12.2.4. Function
12.2.5. North America Drug Discovery Platforms Revenue By Function
12.2.6. End User
12.2.7. North America Drug Discovery Platforms Revenue By End User
2.3. U.S.
12.4. Canada
12.5. Mexico CHAPTER NO. 13: EUROPE DRUG DISCOVERY PLATFORMS MARKET – COUNTRY ANALYSIS
13.1. Europe Drug Discovery Platforms Overview by Country Segment
13.1.1. Europe Drug Discovery Platforms Revenue Share By Region
13.2. Europe
13.2.1. Europe Drug Discovery Platforms Revenue By Country
13.2.2. Solution
13.2.3. Europe Drug Discovery Platforms Revenue By Solution
13.2.4. Function
13.2.5. Europe Drug Discovery Platforms Revenue By Function
13.2.6. End User
13.2.7. Europe Drug Discovery Platforms Revenue By End User
13.3. UK
13.4. France
13.5. Germany
13.6. Italy
13.7. Spain
13.8. Russia
13.9. Rest of Europe CHAPTER NO. 14: ASIA PACIFIC DRUG DISCOVERY PLATFORMS MARKET – COUNTRY ANALYSIS
14.1. Asia Pacific Drug Discovery Platforms Overview by Country Segment
14.1.1. Asia Pacific Drug Discovery Platforms Revenue Share By Region
14.2. Asia Pacific
14.2.1. Asia Pacific Drug Discovery Platforms Revenue By Country
14.2.2. Solution
14.2.3. Asia Pacific Drug Discovery Platforms Revenue By Solution
14.2.4. Function
14.2.5. Asia Pacific Drug Discovery Platforms Revenue By Function
14.2.5. End User
14.2.7. Asia Pacific Drug Discovery Platforms Revenue By End User
14.3. China
14.4. Japan
14.5. South Korea
14.6. India
14.7. Australia
14.8. Southeast Asia
14.9. Rest of Asia Pacific CHAPTER NO. 15: LATIN AMERICA DRUG DISCOVERY PLATFORMS MARKET – COUNTRY ANALYSIS
15.1. Latin America Drug Discovery Platforms Overview by Country Segment
15.1.1. Latin America Drug Discovery Platforms Revenue Share By Region
15.2. Latin America
15.2.1. Latin America Drug Discovery Platforms Revenue By Country
15.2.2. Solution
15.2.3. Latin America Drug Discovery Platforms Revenue By Solution
15.2.4. Function
15.2.5. Latin America Drug Discovery Platforms Revenue By Function
15.2.6. End User
15.2.7. Latin America Drug Discovery Platforms Revenue By End User
15.3. Brazil
15.4. Argentina
15.5. Rest of Latin America CHAPTER NO. 16: MIDDLE EAST DRUG DISCOVERY PLATFORMS MARKET – COUNTRY ANALYSIS
16.1. Middle East Drug Discovery Platforms Overview by Country Segment
16.1.1. Middle East Drug Discovery Platforms Revenue Share By Region
16.2. Middle East
16.2.1. Middle East Drug Discovery Platforms Revenue By Country
16.2.2. Solution
16.2.3. Middle East Drug Discovery Platforms Revenue By Solution
16.2.4. Function
16.2.5. Middle East Drug Discovery Platforms Revenue By Function
16.2.6. End User
16.2.7. Middle East Drug Discovery Platforms Revenue By End User
16.3. GCC Countries
16.4. Israel
16.5. Turkey
16.6. Rest of Middle East CHAPTER NO. 17: AFRICA DRUG DISCOVERY PLATFORMS MARKET – COUNTRY ANALYSIS
17.1. Africa Drug Discovery Platforms Overview by Country Segment
17.1.1. Africa Drug Discovery Platforms Revenue Share By Region
17.2. Africa
17.2.1. Africa Drug Discovery Platforms Revenue By Country
17.2.2. Solution
17.2.3. Africa Drug Discovery Platforms Revenue By Solution
17.2.4. Function
17.2.5. Africa Drug Discovery Platforms Revenue By Function
17.2.6. End User
17.2.7. Africa Drug Discovery Platforms Revenue By End User
17.3. South Africa
17.4. Egypt
17.5. Rest of Africa CHAPTER NO. 18: COMPANY PROFILES
18.1. Schrödinger
18.1.1. Company Overview
18.1.2. Service Portfolio
18.1.3. Financial Overview
18.1.4. Recent Developments
18.1.5. Growth Strategy
18.1.6. SWOT Analysis
18.2. Certara
18.3. PerkinElmer (Revvity)
18.4. Merative (formerly IBM Watson Health)
18.5. Charles River Laboratories
18.6. Evotec SE
18.7. Chemaxon
18.8. OpenEye (Cadence Molecular Sciences)
18.9. Genedata
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the current market size for Drug Discovery Platforms Market, and what is its projected size in 2032?
The Drug Discovery Platforms Market size reached USD 240.70 million in 2024 and is projected to achieve USD 607.68 million by 2032, indicating strong long-term growth.
At what Compound Annual Growth Rate is the Drug Discovery Platforms Market projected to grow between 2025 and 2032?
The Drug Discovery Platforms Market is expected to expand at a CAGR of 11.44% during the forecast period 2025–2032, supported by innovation and global adoption.
Which Drug Discovery Platforms Market segment held the largest share in 2024?
The Software segment dominated with 62% share in 2024, driven by AI-enabled platforms, predictive analytics, and cloud-based computational tools widely adopted by pharma and biotech firms.
What are the primary factors fueling the growth of the Drug Discovery Platforms Market?
Key growth drivers include rising AI integration, growing demand for precision medicine, and increasing outsourcing to CROs, all accelerating adoption of digital drug discovery platforms.
Who are the leading companies in the Drug Discovery Platforms Market?
Major players include Schrödinger, Certara, PerkinElmer (Revvity), Merative, Charles River Laboratories, Evotec SE, Chemaxon, OpenEye (Cadence Molecular Sciences), and Genedata, shaping competitive innovation worldwide.
Which region commanded the largest share of the Drug Discovery Platforms Market in 2024?
North America led with 38% share in 2024, driven by strong R&D investments, advanced healthcare infrastructure, and widespread adoption of AI-enabled and cloud-based platforms.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The global Intravenous (IV) Ibuprofen Market was valued at USD 7.29 billion in 2024 and is projected to reach USD 11.84 billion by 2032, growing at a CAGR of 6.25% during the forecast period.
The global Hypopigmentation Disorder Treatment Market was valued at USD 7.43 billion in 2024 and is projected to reach USD 11.17 billion by 2032, growing at a CAGR of 5.23% during the forecast period.
The global Gastroparesis Drugs Market was valued at USD 6.69 billion in 2024 and is projected to reach USD 9.06 billion by 2032, growing at a CAGR of 3.86% during the forecast period.
Devic's Syndrome Treatment Market size was valued at USD 210.00 million in 2018 to USD 246.32 million in 2024 and is anticipated to reach USD 374.34 million by 2032, at a CAGR of 5.45% during the forecast period.
General Anesthesia Drugs Market size was valued at USD 5.84 billion in 2024 and is anticipated to reach USD 7.72 billion by 2032, at a CAGR of 3.55% during the forecast period.
The Genitourinary Drugs Market was valued at USD 29.7 billion in 2024 and is projected to reach USD 31.91 billion by 2032, growing at a CAGR of 0.9% during the forecast period.
The Appetite Suppressants market size was valued at USD 2,001.40 million in 2018, increased to USD 2,986.65 million in 2024, and is anticipated to reach USD 5,059.01 million by 2032, growing at a CAGR of 6.34% during the forecast period.
Interleukin Inhibitors Market size was valued at USD 32.63 billion in 2024 and is anticipated to reach USD 87.98 billion by 2032, at a CAGR of 13.2% during the forecast period.
Global Catharanthine market size was valued at USD 658.42 million in 2018, increasing to USD 879.91 million in 2024, and is anticipated to reach USD 1,270.26 million by 2032, at a CAGR of 4.37% during the forecast period.
Global Catecholamine market size was valued at USD 2,705.65 million in 2018, increasing to USD 3,997.38 million in 2024, and is anticipated to reach USD 6,669.27 million by 2032, at a CAGR of 6.15% during the forecast period.
The extractable and leachable testing services market size was valued at USD 434.5 million in 2024 and is anticipated to reach USD 735.5 million by 2032, at a CAGR of 6.8 % during the forecast period (2024-2032).
The Global Central Fill Pharmacy Automation Market size was valued at USD 520.0 million in 2018 to USD 806.6 million in 2024 and is anticipated to reach USD 2,194.7 million by 2032, at a CAGR of 13.4 % during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$6999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
